The Patent Finder

Intrabio Ltd.

19 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2037
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 4, 2027
    The maintenance fee for Betahistine, or a Pharmaceutically Acceptable Salt Thereof, and a Monoamine Oxidase Inhibitor, for Use in the Treatment or Prevention of One or More Symptoms of Vertigo in a Subject (US 11,690,830) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
  • 1 fee due Apr 24, 2027
    The maintenance fee for Therapeutic Agents for Neurodegenerative Diseases (US 11,793,782) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,905,670Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive Function
In force
 · High confidence
In forceHigh confidence
US 11,400,067Pharmaceutical Compositions and Uses Directed to Lysosomal Storage Disorders
In force
 · High confidence
In forceHigh confidence
US 11,998,518Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive Function
In force
 · Low confidence
In forceLow confidence
US 12,144,792Therapeutic Agents for Neurodegenerative Diseases
In force
 · High confidence
In forceHigh confidence
US 12,329,733Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive Function
In force
 · High confidence
In forceHigh confidence
US 12,433,862Pharmaceutical Compositions and Uses Directed to Lysosomal Storage Disorders
In force
 · High confidence
In forceHigh confidence
US 12,433,863Pharmaceutical Compositions and Uses Directed to Lysosomal Storage Disorders
In force
 · High confidence
In forceHigh confidence
US 12,797,352Therapeutic Agents for Neurodegenerative Diseases
In force
 · High confidence
In forceHigh confidence
US 12,121,513Betahistine, or a Pharmaceutically Acceptable Salt Thereof, and a Monoamine Oxidase Inhibitor, for Use in the Treatment or Prevention of One or More Symptoms of Vertigo in a Subject
In force
 · Low confidence
In forceLow confidence
US 11,690,830Betahistine, or a Pharmaceutically Acceptable Salt Thereof, and a Monoamine Oxidase Inhibitor, for Use in the Treatment or Prevention of One or More Symptoms of Vertigo in a Subject
In force
 · Medium confidence
In forceMedium confidence
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending

Showing 1 to 5 of 5, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
19/206,473Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive FunctionMay 13, 2025Pending
18/921,779Deuterated Analogs of Acetyl-LeucineOct 21, 2024Pending
18/411,512Therapeutic Agents for Neurodegenerative DiseasesJan 12, 2024Pending
17/999,598The Combination of Acetyl Leucine and 4-AMINOPYRIDINE or Acetazolamide for Treating AtaxiaMay 20, 2021Pending
17/435,784Leucine, Acetyl Leucine, and Related Analogs for Treating DiseaseMar 2, 2020Pending
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited